Lv1
18 积分 2024-09-23 加入
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
2天前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
2天前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
2天前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?
5天前
已完结
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial
5天前
已完结
Phage Display as a Strategy for Designing Organic/Inorganic Biomaterials
1个月前
已完结
Construction of Rabbit Immune Antibody Libraries
2个月前
已完结
Construction of Rabbit Immune Antibody Libraries
2个月前
已完结
Construction of Rabbit Immune Antibody Libraries
2个月前
已完结
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma
2个月前
已完结
皖公网安备34019202002308
